Atrial‐like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial‐selective pharmacology

HD Devalla, V Schwach, JW Ford, JT Milnes… - EMBO molecular …, 2015 - embopress.org
Drugs targeting atrial‐specific ion channels, Kv1. 5 or Kir3. 1/3.4, are being developed as
new therapeutic strategies for atrial fibrillation. However, current preclinical studies carried …
被引用次数：323 相关文章
[PDF] academia.edu

[PDF][PDF] Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology

HD Devalla, V Schwach, JW Ford, JT Milnes… - 2015 - academia.edu
Drugs targeting atrial-specific ion channels, Kv1. 5 or Kir3. 1/3.4, are being developed as
new therapeutic strategies for atrial fibrillation. However, current preclinical studies carried …
[PDF] core.ac.uk

[PDF][PDF] Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology

HD Devalla, V Schwach, JW Ford, JT Milnes… - core.ac.uk
Drugs targeting atrial-specific ion channels, Kv1. 5 or Kir3. 1/3.4, are being developed as
new therapeutic strategies for atrial fibrillation. However, current preclinical studies carried …
[PDF] cordynamics.com

[PDF][PDF] Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology

HD Devalla, V Schwach, JW Ford, JT Milnes… - cordynamics.com
Drugs targeting atrial-specific ion channels, Kv1. 5 or Kir3. 1/3.4, are being developed as
new therapeutic strategies for atrial fibrillation. However, current preclinical studies carried …
[PDF] ugent.be

[PDF][PDF] Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology

HD Devalla, V Schwach, JW Ford, JT Milnes… - backoffice.biblio.ugent.be
Drugs targeting atrial-specific ion channels, Kv1. 5 or Kir3. 1/3.4, are being developed as
new therapeutic strategies for atrial fibrillation. However, current preclinical studies carried …
[PDF] researchgate.net

[PDF][PDF] Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology

HD Devalla, V Schwach, JW Ford, JT Milnes… - researchgate.net
Drugs targeting atrial-specific ion channels, Kv1. 5 or Kir3. 1/3.4, are being developed as
new therapeutic strategies for atrial fibrillation. However, current preclinical studies carried …

Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology

HD Devalla, V Schwach… - EMBO …, 2015 - researchinformation.amsterdamumc …
Drugs targeting atrial-specific ion channels, Kv1. 5 or Kir3. 1/3.4, are being developed as
new therapeutic strategies for atrial fibrillation. However, current preclinical studies carried …

Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology.

HD Devalla, V Schwach, JW Ford, JT Milnes… - EMBO Molecular …, 2015 - europepmc.org
Drugs targeting atrial-specific ion channels, K v 1.5 or K ir 3.1/3.4, are being developed as
new therapeutic strategies for atrial fibrillation. However, current preclinical studies carried …

[引用][C] Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology

HD Devalla, V Schwach, JW Ford, JT Milnes… - EMBO Molecular …, 2015 - elibrary.ru
[PDF] cyberleninka.org

[PDF][PDF] Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology

HD Devalla, V Schwach, JW Ford, JT Milnes… - cyberleninka.org
Drugs targeting atrial-specific ion channels, Kv1. 5 or Kir3. 1/3.4, are being developed as
new therapeutic strategies for atrial fibrillation. However, current preclinical studies carried …